Publicaciones en colaboración con investigadores/as de Catholic University of the Sacred Heart (102)

2024

  1. Abstracts of the 34th World Congress on Ultrasound in Obstetrics and Gynecology, 15-18 September 2024, Budapest, Hungary

    Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology, Vol. 64, pp. 341

  2. Addendum to consensus opinion from International Deep Endometriosis Analysis (IDEA) group: sonographic evaluation of the parametrium

    Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology, Vol. 64, Núm. 2, pp. 275-280

  3. Assessing minimally invasive simple hysterectomy in low risk cervical cancer: set up for the LASH trial

    International Journal of Gynecological Cancer

  4. Multiomics of the intestine-liver-adipose axis in multiple studies unveils a consistent link of the gut microbiota and the antiviral response with systemic glucose metabolism

    Gut

  5. Robotic Versus Laparoscopic Liver Resection in Various Settings: An International Multicenter Propensity Score Matched Study of 10.075 Patients

    Annals of Surgery, Vol. 280, Núm. 1, pp. 108-117

  6. Trends in the characteristics and perioperative outcomes of patients undergoing laparoscopic and open resections for benign liver lesions: An international multicenter retrospective cohort study of 845 patients

    HPB, Vol. 26, Núm. 2, pp. 188-202

2023

  1. An International Expert Delphi Consensus on Defining Textbook Outcome in Liver Surgery (TOLS)

    Annals of Surgery, Vol. 277, Núm. 5, pp. 821-828

  2. Benign descriptors and ADNEX in two-step strategy to estimate risk of malignancy in ovarian tumors: retrospective validation in IOTA5 multicenter cohort

    Ultrasound in Obstetrics and Gynecology, Vol. 61, Núm. 2, pp. 231-242

  3. Best original research presented at the 24th European Congress on Gynaecological Oncology—Best of ESGO 2023

    International Journal of Gynecological Cancer, Vol. 34, Núm. 4, pp. 610-618

  4. Blue Light Exposure: Ocular Hazards and Prevention—A Narrative Review

    Ophthalmology and Therapy, Vol. 12, Núm. 2, pp. 755-788

  5. ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer – Update 2023

    Radiotherapy and Oncology, Vol. 184

  6. Emerging Trends and Future Directions in Skin Cancer Management

    Non-melanoma Skin Cancer: Essentials for Oncologists (CRC Press), pp. 407-426

  7. Genotype-first approach to identify associations between CDH1 germline variants and cancer phenotypes: a multicentre study by the European Reference Network on Genetic Tumour Risk Syndromes

    The Lancet. Oncology, Vol. 24, Núm. 1, pp. 91-106

  8. Impact of body composition in advanced hepatocellular carcinoma: A subanalysis of the SORAMIC trial

    HEPATOLOGY COMMUNICATIONS, Vol. 7, Núm. 6

  9. Interventional Radiotherapy (Brachytherapy) for the Treatment of Primary Lesions in Nasal Vestibule Malignancies

    Malignancies of the Nasal Vestibule: A New Perspective on Classification, Staging, and Treatment (Springer International Publishing), pp. 135-144

  10. Minimally invasive versus open liver resection for hepatocellular carcinoma in the elderly: international multicentre propensity score-matched study

    British Journal of Surgery, Vol. 110, Núm. 8, pp. 927-930

  11. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆

    Annals of Oncology, Vol. 34, Núm. 10, pp. 833-848

  12. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial

    Annals of Oncology, Vol. 34, Núm. 8, pp. 681-692

  13. Prognostic role of radiomics-based body composition analysis for the 1-year survival for hepatocellular carcinoma patients

    Journal of Cachexia, Sarcopenia and Muscle, Vol. 14, Núm. 5, pp. 2301-2309

  14. Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer

    European Journal of Cancer, Vol. 189